Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03630055 · ClinicalTrials.gov registry record · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
A Phase 3 study of Radial Artery Occlusion, sponsored by Ottawa Heart Institute Research Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,800
- Enrollment target
- 3
- Study locations
NCT03630055: Recruiting Phase 3 study of Radial Artery Occlusion, sponsored by Ottawa Heart Institute Research Corporation.
NCT03630055 is a Phase 3 study of Radial Artery Occlusion that is actively recruiting participants, run by Ottawa Heart Institute Research Corporation. The registered enrollment target is 1,800 participants. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03630055, a Phase 3 study of Radial Artery Occlusion, is actively recruiting participants, sponsored by Ottawa Heart Institute Research Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,800 participants
- Enrollment target
- 3
- Study locations
Study Summary
Coronary angiography is performed to evaluate for obstructive coronary artery disease. This is commonly performed via the transfemoral or transradial approach with the latter increasing in frequency. One of the most common complications of transradial access is radial artery occlusion occurring in \~5% of patients which prohibits the use of the radial artery in the future. There is evidence to support the use of intraprocedural anticoagulation to mitigate the risk of radial artery occlusion however the role of post-procedural anticoagulation has not been previously evaluated. Rivaroxaban is a direct oral anticoagulant (DOAC) with a safety profile superior to that of vitamin K antagonists. Given the safety profile, ease of use, and feasibility of DOAC therapy, our study will endeavor to evaluate the use of rivaroxaban 15mg orally once daily for 7 days after transradial access and the impact this has on the rate of radial artery occlusion.
Conditions Studied
Interventions
- DRUG Rivaroxaban 15 MG Oral Tablet [Xarelto]
Study Locations (3)
Ontario
- Kingston Health Sciences Center - Kingston
- University of Ottawa Heart Institute - Ottawa
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2018-10-03 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03630055
The ClinicalTrials.gov registry entry for NCT03630055 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ottawa Heart Institute Research Corporation, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Radial Artery Occlusion appearing as the primary indexed condition, and to 1 intervention - of which Rivaroxaban 15 MG Oral Tablet [Xarelto] is the first listed.
NCT03630055 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Ontario, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03630055 about?
NCT03630055 is a clinical study titled "Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion". Coronary angiography is performed to evaluate for obstructive coronary artery disease. This is commonly performed via the transfemoral or transradial approach with the latter increasing in frequency. One of the most common complications of transradial access is radial artery occlusion occurring in \...
What is the current status of trial NCT03630055?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,800 participants. The study started on 2018-10-03. Estimated completion is 2026-06-30.
What conditions does trial NCT03630055 study?
This clinical trial studies the following conditions: Radial Artery Occlusion.
What interventions are being tested in trial NCT03630055?
The interventions under investigation include: Rivaroxaban 15 MG Oral Tablet [Xarelto] (DRUG).
Who is sponsoring clinical trial NCT03630055?
This trial is sponsored by Ottawa Heart Institute Research Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03630055 being conducted?
This trial has 3 study locations across Minnesota, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.